Glucagon‐like peptide‐1 receptor expression in the human eye

Semaglutide is a human glucagon‐like peptide‐1 (GLP‐1) analogue that is in development for the treatment of type 2 diabetes. In the pre‐approval cardiovascular outcomes trial SUSTAIN 6, semaglutide was associated with a significant increase in the risk of diabetic retinopathy (DR) complications vs p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Hebsgaard, Josephine B., Pyke, Charles, Yildirim, Emre, Knudsen, Lotte B., Heegaard, Steffen, Kvist, Peter H.
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2018
Témata:
Brief Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6099507/
https://ncbi.nlm.nih.gov/pubmed/29707863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13339
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky